Category: Preparing for First-In-Human Studies

Founders comparing FIH medical device clinical trials Latin America vs Australia usually start with one slide: Australia’s 43.5% Research & Development Tax Incentive. That offset is real for eligible entities. It is also not the whole operating picture. Once you price site access, timezone friction, principal-investigator bandwidth, and whether the file can survive an FDA foreign-data conversation under 21 CFR 812.28, the Australia-versus-Latin-America choice stops being a rebate math problem and becomes a calendar-and-execution problem.

I am Julio Martinez-Clark, CEO of bioaccess®. This brief is the operational cut that sits beside our published Australian R&D rebate math and the live Australia comparison hub. It is not tax advice. Confirm current R&DTI rules with your Australian advisers. Confirm study-specific clocks with a proposal.

1. Why founders look to Australia

Australia earned its reputation with early-phase sponsors for four reasons that still matter for medical devices:

• No US IND/IDE as a precondition to start. Under the Clinical Trial Notification (CTN) pathway, many device investigations can open without a TGA clinical pre-review of the protocol. English-language HREC review and site governance still apply. The CTN is not a free pass; it is a different gate than a US Investigational Device Exemption.
• The 43.5% refundable R&D tax offset for eligible companies with aggregated turnover under A$20M (figures in force for FY2025–26 and FY2026–27 on our rebate article). Clinical-trial spend can sit outside the standard A$4M annual refund cap when the activities qualify. That is financing, not a 43.5% invoice discount.
• English end-to-end. Protocol, consent, monitoring reports, and source can stay in English. For US regulatory affairs teams that have never run a Spanish ethics packet, that alone can feel like risk reduction.
• Hospital-grade sites and ISO 14155 culture. Australian private HRECs (including Bellberry-style pathways) and public-hospital National Mutual Acceptance processes are documented. Experienced device CROs and hospital implant sites exist. For non-surgical wearables or diagnostic devices that fit a Phase I unit model, the Australian infrastructure is mature.

None of that is marketing fluff. If your board already has an Australian subsidiary, a booked HREC slot, and a PI who has room, Australia can be the right first country. The question is whether that combination is what you actually have — or what the slide assumes you will have after six more months of contracting.

2. Hidden friction: saturation, timezone, and travel

The rebate slide rarely shows the three frictions US medtech operators hit after the LOI:

Site and PI saturation. Australia’s device FIH market is smaller than the marketing deck implies. A handful of high-volume hospitals and implant-capable investigators take a disproportionate share of early-feasibility work. When several US startups chase the same orthopedic, cardiovascular, or neurotech wards in Melbourne, Sydney, or Brisbane, start-up stops being “6–8 weeks to HREC” and becomes a queue for investigator time, theatre slots, and competing protocols. Drug Phase I units are abundant; Class III implant bandwidth is not.

Fourteen to sixteen hours from US Eastern Time. Same-day PI questions turn into next-calendar-day loops. Monitoring visits, serious-adverse-event triage, and FDA Pre-Sub prep calls stack against Australian business hours. Your clinical lead in Boston wakes up to yesterday’s answers. That is manageable for a single Phase I cohort. It is expensive when the device needs iterative implant feedback, imaging reads, and sponsor–CRO–PI huddles in the first ten patients.

Travel and presence cost. A US engineering or medical director who needs to be in theatre for the first cases buys long-haul flights, jet lag, and limited week blocks. Latin America FIH hubs that sit on or near US Eastern Time (Panama City is the clearest example on our public hubs) let the same person leave Miami in the morning and stand in the OR the same afternoon. That is not tourism. It is how you keep design engineers inside the first-implant feedback loop without burning a week of runway per trip.

Gross cash versus rebate recovery. As our rebate math article already states: you fund the Australian gross cost now and recover part of it after year-end lodgement — only if an eligible Australian entity exists, aggregated turnover clears the test (connected entities count), and AusIndustry accepts the activities. Rebate-advance lenders exist; they charge. On a gross cash basis, bioaccess® program experience still puts Latin America roughly 35–45% below Australia; after a fully captured rebate the gap can narrow to about 5–15%, and in some programs reverse. Treat that as published orientation, not a guarantee for your Class III cohort.

Entity and compliance overhead. Standing up the Australian subsidiary, registering R&D activities, and defending the claim is real work. Teams that treat the 43.5% figure as a coupon often under-budget the local tax and legal stack that makes the coupon collectible.

3. The Latin America counter-proposition

Latin America’s offer for first-in-human and early-feasibility device work is not “cheaper Australia.” It is a different operating system built around calendar proximity to US teams, investigator engagement, and investigation desks that do not require a US IDE to start.

Published start-up bands. On bioaccess® country hubs and FIH guides, coordinated programs in lead geographies such as Panama commonly show ethics in about 3–5 weeks and roughly 6–8 weeks to first patient when the Spanish package, insurance certificate, and investigational import are ready. El Salvador’s public language for CNEIS ethics plus SRS clinical-investigation authorization sits in a 30–60 day band. Those are investigation clocks — not commercial registro. Ask for a study-specific Gantt; do not paste a hub median onto a board slide as a promise.

Same-timezone US proximity. Panama City runs on US Eastern Time. Miami is a short flight. For US sponsors, that means PI calls land in the same workday, monitoring can be planned without a 16-hour offset, and the medical director can attend early implants without a Pacific crossing. Other LATAM hubs add Spanish-language depth and surgical volume; the timezone argument is strongest where clocks align with US Eastern or Central.

PI engagement and surgical volume. Early-feasibility device work needs investigators who already operate in the indication and hospitals that will treat a novel implant as a protocol, not a legal crisis. Latin American tertiary centers in published FIH geographies have run ISO 14155-style device investigations with bilingual teams. The operating move is named PI and named ward in the feasibility deliverable — not a country flag on a map.

Where we point new FIH work. Prefer Latin America destinations that publish usable investigation frameworks for high-risk devices — Panama (MINSA / CNBI under Ley 84 and Decreto Ejecutivo No. 21 of 2026), El Salvador (CNEIS / SRS), and other hubs already on the clinical-trials hub — when the protocol needs a lead investigation desk. Colombia remains a strong market-access geography. The public line still stands: INVIMA clinical-trial approval timelines have become unpredictable, so bioaccess® does not currently recommend Colombia for new first-in-human execution. Keep INVIMA on the commercial registration track. Do not flip that sentence.

What LATAM is not. It is not a reason to skip ISO 14155 monitoring, device accountability, or a coherent preclinical narrative. Thin trial master files buy investor slides and FDA friction. It is also not automatic commercial sale: trial authorization and sanitary registration are different desks in every country we work.

4. Data compatibility for FDA — 21 CFR 812.28

Foreign clinical data can support an IDE or a device marketing application when the investigation meets 21 CFR 812.28 (final rule, 83 FR 7386, 21 February 2018). Eligibility is not clearance. Design for the rule; do not treat geography as a substitute for GCP.

Section 812.28(a) requires, in substance:

1. Good clinical practice — design, conduct, monitoring, auditing, recording, analysis, and reporting that keep data credible and protect subjects, including independent ethics-committee review before initiation and documented freely given informed consent. FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28.
2. Supporting information in 812.28(b) for significant-risk devices — investigators and sites; protocol and results; identity of the investigational device to the US device or a detailed comparison; IEC identity; consent, monitoring, and investigator GCP training.
3. FDA can validate the data through onsite inspection or other means if the agency deems it necessary. A file that cannot be inspected is not an 812.28 file.

Australia’s English TMF can feel easier to hand an inspector. That advantage disappears if the Australian site never had bandwidth to enroll, or if the sponsor never built monitoring and device accountability. Latin America files written in Spanish at the ethics desk still need English-capable source, EDC, and accountability that survive an FDA conversation — plus a Pre-Sub / Q-Sub before you lock endpoints when the Panama or El Salvador cohort is meant to support a later US IDE (written feedback in 75 calendar days is the usual Pre-Sub clock).

Parallel clause already on our FDA-acceptance materials: 21 CFR 814.15 for foreign data in PMA applications. Plan for 812.28(a), not the residual 812.28(e) lifeline.

How to choose this week

1. Write two columns: Australia (entity + HREC + named PI + gross cash + rebate recovery timing) versus Latin America lead jurisdiction (ethics desk + investigational importer + 6–8 week band + US timezone plan).
2. Price presence. Count flights and same-day PI loops for the first ten patients, not only per-patient fees.
3. Name the 812.28 owner before first implant — TMF, device accountability, consent elements aligned to 21 CFR 50.25 if FDA use is intended.
4. Keep commercial registro off the FIH critical path. Market-access holder strategy is a different SKU from investigation authorization.

If your Australian path already has a free PI and a funded subsidiary, run the rebate math honestly and go. If you are still shopping for investigator time against a 14–16 hour offset, put Latin America on the same slide with published clocks from the clinical-trials hub and the Australia compare page — and keep Colombia on market access, not as the default new-FIH recommendation.

Related: Australia vs Latin America R&D tax incentive, compare Australia, and LATAM clinical trials. For a study-specific calendar, bring protocol stage, device risk class, intended US filing, and whether the investigational unit matches the US unit.